Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
Carel W le RouxShuyu ZhangLouis J AronneRobert F KushnerAriana M ChaoSriram MachineniJulia DunnFarai B ChigutsaNadia N AhmadMathijs C BunckPublished in: Obesity (Silver Spring, Md.) (2022)
The extensive assessment of once-weekly tirzepatide in the global SURMOUNT program will detail the clinical effects of this first-in-class glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in chronic weight management.